https://www.selleckchem.com/pr....oducts/fatostatin.ht
Using real-world Japanese postmarketing data, we characterized interstitial lung disease (ILD) development during the second- or later-line osimertinib treatment for EGFR mutation-positive NSCLC. #link# Retrospective radiologic image evaluation of patients developing ILD was also performed. Patients who had ILD events reported as an adverse drug reaction by their physicians and who were assessed as having developed ILD as assessed by an ILD expert committee in Japan were included. Among 3578 patients, 252 ILD events were reported in
Me gusta
Comentario
Compartir
